Clinical Trials Using Bendamustine Hydrochloride

Clinical trials are research studies that involve people. The clinical trials on this list are studying Bendamustine Hydrochloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-15 of 15
  • Bendamustine Hydrochloride, Rituximab, Ibrutinib, and Venetoclax in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma

    This phase I trial studies the side effects and best dose of venetoclax when giving together with bendamustine hydrochloride, rituximab, and ibrutinib in treating patients with mantle cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as bendamustine hydrochloride and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bendamustine hydrochloride, rituximab, ibrutinib, and venetoclax may work better in treating patients with mantle cell lymphoma.
    Location: 7 locations

  • Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

    Patients with high tumor burden, low grade follicular lymphoma that has never been treated, will receive venetoclax in combination with obinutuzumab and bendamustine. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with follicular lymphoma. Venetoclax may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding venetoclax to obinutuzumab and bendamustine improves the response (the tumor shrinks or disappears) in patients with follicular lymphoma. As of 9 / 5 / 2018, a higher than expected incidence of tumor lysis syndrome (TLS) was experienced among patients receiving venetoclax, obinutuzumab and bendamustine on Cycle 1, Day 1 of treatment. TLS is caused by the fast breakdown of cancer cells. These patients developed an increase in some of their blood tests (uric acid, phosphorus, potassium and / or creatinine). They received a medication called rasburicase and continued with treatment. It is unclear if the TLS was due to the venetoclax or the standard treatment of obinutuzumab and bendamustine. For the remaining patients, venetoclax will start on Cycle 2, Day 1 (previously Cycle 1, Day 1).
    Location: 8 locations

  • Carfilzomib, Bendamustine Hydrochloride, and Rituximab in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    This phase Ib trial studies the side effects and best dose of carfilzomib when given together with bendamustine hydrochloride and rituximab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving carfilzomib together with bendamustine hydrochloride and rituximab may be a better treatment for B-cell non-Hodgkin lymphoma.
    Location: 3 locations

  • A Study of Brentuximab Vedotin in Adults Age 60 and Above With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

    This trial will study brentuximab vedotin to find out whether it is an effective treatment in patients 60 years or older for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). The study will look at brentuximab vedotin alone and combined with other drugs.
    Location: 4 locations

  • Gemcitabine, Bendamustine Hydrochloride, and Nivolumab in Treating Patients with Relapsed or Refractory Classic Hodgkin Lymphoma

    This phase I / II trial studies the side effects and best dose of gemcitabine, bendamustine hydrochloride, and nivolumab when given together and to see how well they work in treating patients with classic Hodgkin lymphoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as gemcitabine and bendamustine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving gemcitabine, bendamustine hydrochloride, and nivolumab may work better in treating patients with classic Hodgkin lymphoma.
    Location: 2 locations

  • INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

    The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.
    Location: 2 locations

  • A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

    The purpose of the study is to compare the safety and efficacy of MOR208 with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
    Location: 3 locations

  • Genetically Engineered Cells (ATLCAR.CD30 T Cells) for the Treatment of Relapsed or Refractory CD30 Positive Peripheral T Cell Lymphoma

    This phase II trial studies how well genetically engineered cells (ATLCAR.CD30 T cells) work in treating patients with CD30 positive peripheral T cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). T cells are special types of blood cells. They can find and destroy other cells that may cause disease or cancer. However, sometimes cancer cells can hide from T cells and grow into tumors. Genes make up the chemical structure carrying information that may determine human characteristics (i.e., eye color, height and sex). In this study, a gene that makes an antibody called anti-CD30 is put inside T cells, which may make T cells better at recognizing and destroying CD30 positive peripheral T cell lymphoma cancer cells.
    Location: 2 locations

  • Bendamustine, Rituximab, Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia

    This phase II trial studies how well bendamustine, rituximab, and venetoclax in treating patients with chronic lymphocytic leukemia or small lymphocytic leukemia. Drugs used in chemotherapy, such as bendamustine, rituximab, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may also block proteins present on chronic lymphocytic leukemia cells. Giving bendamustine and rituximab followed by venetoclax may increase response to therapy and reduce the risk of complications.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • ATLCAR.CD30.CCR4 with or without ATLCAR.CD30 in Treating Patients with Relapsed or Refractory CD30+ Hodgkin Lymphoma or Cutaneous T-cell Lymphoma

    This phase I trial studies best dose and how well autologous CCR4-CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes (ATLCAR.CD30.CCR4) with or without autologous CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes (ATLCAR.CD30) works in treating patients with CD30+ Hodgkin lymphoma or cutaneous T-cell lymphoma that has come back or that does not respond to treatment. T cells or T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with bacteria or viruses. Modified T-cells called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD30 antigen (ATLCAR.CD30) and autologous T lymphocyte chimeric antigen receptor cells targeted against the CD30 antigen with CCR4 (ATLCAR.CD30.CCR4) may help the cells move to regions in the body where the cancer is present and may improve the body's ability to fight Hodgkin lymphoma or cutaneous T-cell lymphoma.
    Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

  • Rituximab, Bendamustine Hydrochloride, Melphalan and Stem Cell Transplant in Treating Elderly Participants with Relapsed or Refractory B-cell Lymphoma

    This phase I / II trial studies the side effects and best dose of rituximab, bendamustine hydrochloride and melphalan and how well they work in treating elderly participants with B-cell Lymphoma that has come back or does not respond to treatment before undergoing stem cell transplant. Immunotherapy with monoclonal antibodies, such as rituximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as bendamustine hydrochloride and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a transplant helps kill any cancer cells that are in the body and helps make room in the patient’s bone marrow for new blood-forming cells (stem cells) to grow.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Cellular Immunotherapy following Chemotherapy in Treating Patients with Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

    This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has come back. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Bendamustine Hydrochloride and Rituximab Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trial studies how well bendamustine hydrochloride and rituximab followed by rituximab and lenalidomide work in treating patients with previously untreated chronic lymphocytic leukemia or small cell lymphocytic lymphoma. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or stopping them from spreading. Monoclonal antibodies, such as rituximab, block cancer growth in different ways by targeting certain cells. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving bendamustine hydrochloride and rituximab followed by rituximab and lenalidomide may kill more cancer cells.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Inotuzumab Ozogamicin, Fludarabine Phosphate, Bendamustine Hydrochloride, and Rituximab before Donor Stem Cell Transplant in Treating Patients with Lymphoid Malignancies

    This phase I / II trial studies the side effects and the best dose of inotuzumab ozogamicin when given together with fludarabine phosphate, bendamustine hydrochloride, and rituximab before donor stem cell transplant in treating patients with lymphoid malignancies. Giving chemotherapy drugs, such as fludarabine phosphate and bendamustine hydrochloride, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells or abnormal cell and helps stop the patient's immune system from rejecting the donor's stem cells. Immunotherapy with monoclonal antibodies, such as inotuzumab ozogamicin and rituximab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cell from a donor can make an immune system response against the body's normal cells. Giving fludarabine phosphate and bendamustine hydrochloride before the transplant together with anti-thymocyte globulin and tacrolimus may stop this from happening.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

    Eligible untreated patients will receive single arm venetoclax, bendamustine and rituximab as induction therapy. After 6 cycles, maintenance rituximab may be administered per physician discretion. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax may make the cancer cells sensitive to chemotherapy. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia